A drug in Phase I clinical trials is showing good results in treatment for metastatic breast cancer when combined with paclitaxel. AVEO Pharmaceutical Company’s tivozanib is a selective VEGF receptor inhibitor. Dr. Erica L. Mayer, medical oncologist at the Breast Oncology Center, Dana-Farber Institute, presented a poster session indicating positive results for tivozanib, combined with Taxol®, including progression-free survival. Since Phase I demonstrated safety for doses up to full dosage, we should be watching for announcements of Phase II studies. Additionally, Phase I clinical trials of tivozanib have reported no severe side effects.
One wonders if this could be the next drug of promise to fill the gap left by the exit of Avastin®.
Time for more reading and talking to our oncologists.
5 6 7 8
© 2004–2010 Donna Peach. All rights reserved.